IJMPD | Current techniques and future directions in antibiotic resistance breakers

Indexing and Abstracting

Current techniques and future directions in antibiotic resistance breakers

Danyar Hameed M Amin

International Journal of Medical, Pharmacy and Drug Research(IJMPD), Vol-5,Issue-4, July - August 2021, Pages 16-21 , 10.22161/ijmpd.5.4.3

Download | Downloads : 6 | Total View : 798

Article Info: Received: 05 Jul 2021; Received in revised form: 03 Aug 2021; Accepted: 10 Aug 2021; Available online: 17 Aug 2021

Abstract:

A phenolic molecule found in the curry plant, curcumin, has numerous pharmacological actions, including an antibacterial impact. An environmental, nontuberculous, rapidly growing mycobacterium known as Mycobacterium abscessus is emerging as a serious human pathogen, especially in lung infections, as it possesses broad‐spectrum resistance to antibiotics, possesses a high level of biofilm capability, and has a low prevalence of disease. To identify antimicrobial and antivirulence activity, the researchers wished to examine the antimicrobial and antivirulence activity of curcumin, as well as the ability to work together with medications against a clinical specimen from a lady admitted to hospital with suspected tuberculosis. While strain B developed resistance to amikacin, clarithromycin, ciprofloxacin, and linezolid, strain B exhibited synergism (fractional inhibitory concentration index <0.5) with curcumin, indicating resistance to amikacin, clarithromycin, ciprofloxacin, and linezolid. Inhibiting 4‐ and 8‐day mature biofilms completely with 1/8 MIC curcumin was enough to greatly limit motility. When used together, curcumin and amikacin reduced microbial aggregation while also causing considerable cell death. The main effect found when curcumin was the dominating compound was the disruption of 4- and 8-day biofilms. The current findings confirm prior research that suggests that curcumin may be a resistance buster against antibiotics.

Keywords:

antibiotic resistance breakers; efflux pump inhibitors; membrane permeabilisers; beta-lactamase inhibitors.

References:

[1] Laws, M., Shaaban, A., & Rahman, K. M. (2019). Antibiotic resistance breakers: current approaches and future directions. FEMS microbiology reviews, 43(5), 490-516.
[2] Brown, D. (2015). Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?. Nature reviews Drug discovery, 14(12), 821-832.
[3] Reza, A., Sutton, J. M., & Rahman, K. M. (2019). Effectiveness of efflux pump inhibitors as biofilm disruptors and resistance breakers in gram-negative (ESKAPEE) bacteria. Antibiotics, 8(4), 229.
[4] Kant, S., Asthana, S., Missiakas, D., & Pancholi, V. (2017). A novel STK1-targeted small-molecule as an “antibiotic resistance breaker” against multidrug-resistant Staphylococcus aureus. Scientific reports, 7(1), 1-19.
[5] Akther, T., Priya, S., Sah, S. K., Khan, M. S., & Hemalatha, S. (2019). Ta-AgNps are potential antimicrobial resistance breakers. Journal of Nanostructures, 9(2), 376-383.
[6] Marini, E., Di Giulio, M., Magi, G., Di Lodovico, S., Cimarelli, M. E., Brenciani, A., ... & Facinelli, B. (2018). Curcumin, an antibiotic resistance breaker against a multiresistant clinical isolate of Mycobacterium abscessus. Phytotherapy research, 32(3), 488-495.
[7] Ko, H. H., Lareu, R. R., Dix, B. R., & Hughes, J. D. (2017). Statins: antimicrobial resistance breakers or makers?. PeerJ, 5, e3952.
[8] Abiraami, V. S., & Gowrie, S. U. (2019). Sprouts as functional food-an approach towards the identification of natural antibiotic resistance breakers. Journal of Drug Delivery and Therapeutics, 9(1-s), 23-35.
[9] Wright, G. D. (2016). Antibiotic adjuvants: rescuing antibiotics from resistance. Trends in microbiology, 24(11), 862-871.
[10] Bai, J., Zhu, X., Zhao, K., Yan, Y., Xu, T., Wang, J., ... & Qu, D. (2019). The role of ArlRS in regulating oxacillin susceptibility in methicillin-resistant Staphylococcus aureus indicates it is a potential target for antimicrobial resistance breakers. Emerging microbes & infections, 8(1), 503-515.
[11] Ranjani, S., Shariq Ahmed, M., Ruckmani, K., & Hemalatha, S. (2020). Green nanocolloids control multi drug resistant pathogenic bacteria. Journal of Cluster Science, 31(4), 861-866.
[12] Hind, C. K., Dowson, C. G., Sutton, J. M., Jackson, T., Clifford, M., Garner, R. C., & Czaplewski, L. (2019). Evaluation of a library of FDA-approved drugs for their ability to potentiate antibiotics against multidrug-resistant Gram-negative pathogens. Antimicrobial agents and chemotherapy, 63(8), e00769-19.
[13] González-Bello, C. (2017). Antibiotic adjuvants–A strategy to unlock bacterial resistance to antibiotics. Bioorganic & medicinal chemistry letters, 27(18), 4221-4228.
[14] Andersson, D. I., Balaban, N. Q., Baquero, F., Courvalin, P., Glaser, P., Gophna, U., ... & Tønjum, T. (2020). Antibiotic resistance: turning evolutionary principles into clinical reality. FEMS Microbiology Reviews, 44(2), 171-188.
[15] Dersch, P., Khan, M. A., Mühlen, S., & Görke, B. (2017). Roles of regulatory RNAs for antibiotic resistance in bacteria and their potential value as novel drug targets. Frontiers in microbiology, 8, 803.
[16] Wang, M., Liu, H., Cheng, X., Zhang, B., Cai, C., & Wang, J. (2019). Hydrothermal treatment of lincomycin mycelial residues: Antibiotic resistance genes reduction and heavy metals immobilization. Bioresource technology, 271, 143-149.
[17] Hunter, P. (2020). A war of attrition against antibiotic resistance: current strategies try to keep antibiotic resistance at bay and further encourage research to produce genuinely novel antibacterials. EMBO reports, 21(6), e50807.
[18] Kauss, T., Arpin, C., Bientz, L., Nguyen, P. V., Vialet, B., Benizri, S., & Barthélémy, P. (2020). Lipid oligonucleotides as a new strategy for tackling the antibiotic resistance. Scientific reports, 10(1), 1-9.
[19] Di Lodovico, S., Napoli, E., Di Campli, E., Di Fermo, P., Gentile, D., Ruberto, G., ... & Di Giulio, M. (2019). Pistacia vera L. oleoresin and levofloxacin is a synergistic combination against resistant Helicobacter pylori strains. Scientific reports, 9(1), 1-10.
[20] Mengesha, Y., Manaye, B., & Moges, G. (2020). Assessment of public awareness, attitude, and practice regarding antibiotic resistance in Kemissie Town, Northeast Ethiopia: community-based cross-sectional study. Infection and Drug Resistance, 13, 3783.
[21] Dar, D., & Sorek, R. (2017). Regulation of antibiotic-resistance by non-coding RNAs in bacteria. Current opinion in microbiology, 36, 111-117.
[22] Vuotto, C., Longo, F., Pascolini, C., Donelli, G., Balice, M. P., Libori, M. F., ... & Varaldo, P. E. (2017). Biofilm formation and antibiotic resistance in Klebsiella pneumoniae urinary strains. Journal of applied microbiology, 123(4), 1003-1018.
[23] Blair, J. M., Richmond, G. E., & Piddock, L. J. (2014). Multidrug efflux pumps in Gram-negative bacteria and their role in antibiotic resistance. Future microbiology, 9(10), 1165-1177.
[24] Hunter, P. (2015). Antibiotic discovery goes underground: The discovery of teixobactin could revitalise the search for new antibiotics based on the novel method the researchers used to identify the compound. EMBO reports, 16(5), 563-565.
[25] Amin, D. H. M., & Qadir, C. N. (2020). Prevalence of infective agents on equipment used in female cosmetic centers in Sulaymaniyah Governorate-Iraq. Eurasian Journal of Biosciences, 14(2), 5939-5941.
[26] Füchtbauer, S., Mousavi, S., Bereswill, S., & Heimesaat, M. M. (2021). Antibacterial properties of capsaicin and its derivatives and their potential to fight antibiotic resistance–A literature survey. European Journal of Microbiology and Immunology, 11(1), 10-17.
[27] Evans, J. J., & Bolz, D. D. (2019). Regulation of virulence and antibiotic resistance in Gram-positive microbes in response to cell wall-active antibiotics. Current opinion in infectious diseases, 32(3), 217.
[28] Buckland, D. (2017). Antimicrobial resistance and the race to find new antibiotics. Prescriber, 28(1), 12-15.
[29] Blount, K. F., & Breaker, R. R. (2006). Riboswitches as antibacterial drug targets. Nature biotechnology, 24(12), 1558-1564.
[30] Cedraro, N., Cannalire, R., Astolfi, A., Mangiaterra, G., Felicetti, T., Vaiasicca, S., ... & Sabatini, S. (2021). From quinoline to quinazoline‐based S. aureus NorA efflux pump inhibitors by coupling focused scaffold hopping approach and pharmacophore search. ChemMedChem.
[31] Mezzatesta, M. L., Gona, F., & Stefani, S. (2012). Enterobacter cloacae complex: clinical impact and emerging antibiotic resistance. Future microbiology, 7(7), 887-902.
[32] Joshi, P., Khan, Z. A., Tandle, R., Harshe, A., Bhutada, A., & Gogavale, S. (2019). Antibiotic Susceptibility Profile and Prevalence Pattern of Gram Negative Pathogens in Tertiary Care Hospital. Asian Journal of Research in Medical and Pharmaceutical Sciences, 1-9.
[33] Piddock, L., Garneau-Tsodikova, S., & Garner, C. (2016). Ask the experts: how to curb antibiotic resistance and plug the antibiotics gap?. Future medicinal chemistry, 8(10), 1027-1032.
[34] Roth, A., & Breaker, R. R. (2013). Conserved sequences associated with myriad antibiotic resistance genes are integron components and not aminoglycoside riboswitches. Cell, 153(7), 1417.
[35] Alabdullatif, M., & Alrehaili, J. (2020). Three Years of Evaluation to Determine Reduction of Antibiotic Resistance in Gram-Negative Bacteria by the Saudi National Action Plan. Infection and Drug Resistance, 13, 3657.
[36] Crofts, T. S., Gasparrini, A. J., & Dantas, G. (2017). Next-generation approaches to understand and combat the antibiotic resistome. Nature Reviews Microbiology, 15(7), 422-434.
[37] Rezzoagli, C., Archetti, M., Mignot, I., Baumgartner, M., & Kümmerli, R. (2020). Combining antibiotics with antivirulence compounds can have synergistic effects and reverse selection for antibiotic resistance in Pseudomonas aeruginosa. PLoS biology, 18(8), e3000805.
[38] Kim, J. N., Blount, K. F., Puskarz, I., Lim, J., Link, K. H., & Breaker, R. R. (2009). Design and antimicrobial action of purine analogues that bind Guanine riboswitches. ACS chemical biology, 4(11), 915-927.
[39] Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K., Wertheim, H. F., Sumpradit, N., ... & Cars, O. (2013). Antibiotic resistance—the need for global solutions. The Lancet infectious diseases, 13(12), 1057-1098.
[40] Brown, D. (2016). Erratum: Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?. Nature Reviews Drug Discovery, 15(2), 143-143.
[41] Satras, K. B. (2019). Prevalence and Susceptibility Analysis of Gram-Negative Pathogens in Super Specialty Tertiary Care Centers, Pune in India from January 2018-January 2019. Microbiology Research Journal International, 1-9.
[42] Tulara, N. K. (2018). Efficacy and Safety of Novel Antibiotic Adjuvant Entity in Hospital Acquired Pneumonia Treatment. Journal of Advances in Medicine and Medical Research, 1-8.
[43] Palazzotti, D., Bissaro, M., Bolcato, G., Astolfi, A., Felicetti, T., Sabatini, S., ... & Moro, S. (2019). Deciphering the molecular recognition mechanism of multidrug resistance Staphylococcus aureus NorA efflux pump using a supervised molecular dynamics approach. International journal of molecular sciences, 20(16), 4041.
[44] Amin, D. H. M., Guler, E., & Baddal, B. (2020). Prevalence of Panton-Valentine leukocidin in methicillin-resistant Staphylococcus aureus clinical isolates at a university hospital in Northern Cyprus: a pilot study. BMC research notes, 13(1), 1-7.